About ABIVAX

Company Description

Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer.

As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (obefazimod) as well as liver cancer (ABX196). Our mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.

Headquarters

5 Rue de la Baume, 75008 Paris – France

Shareholder information

Shares outstanding

16,740,135

IPO

June 26, 2015

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.